News Brisk trade in risky three-drug 'bet' option after BMS/Celge... Bristol-Myers Squibb’s $74 billion merger with Celgene went ahead this week after clearance from US competition regulators, and the focus has shifted on to whether Celgene shareholders will
News Merck partners Remepy in PDURS-focused alliance Merck KGaA has started working with Remepy on the development of hybrid drugs that combine medicines with digital therapeutics.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
